| | | | | | Préparation | Taille des prés. | PEF | PP | QP | CQ | Composition | Titulaire de l'aut. | Cat. | | | | |
|---|
|
| | | IPro | IPat | | Casgevy 4-13 x 10e6
cells/ml | | DDP | DDP | N.O. | | | Vertex
Pharmaceuticals (CH)
GmbH | A | FB | | G |  |
| | | IPro | IPat | | Ebvallo | | DDP | DDP | N.O. | | | Pierre Fabre Pharma SA | A | FB | | G | |
| | | IPro | IPat | | BILAXIN Ophta 6 mg / ml | 5 ml | DDP | DDP | N.O. | | Collyre: Bilastinum 6 mg/ml | A. Menarini GmbH | D | FB | | G | |
| | | IPro | IPat | | Imodium ‐ P - C | 20 Gélule(s) | 3.87 | 6.85 | 40% | | Capsules: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II
(Switzerland) GmbH | D / LS / SO | FB | | G | |
| | | IPro | IPat | | Imodium - C | 60 Gélule(s) | 9.40 | 26.60 | 40% | | Capsules: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II
(Switzerland) GmbH | B / LS / SO | FB | | G | |
| L | | IPro | IPat | | Microlax | 4 x 5 ml | 4.15 | 7.65 | 10% | | Lavement: 3 Principes actifs | JNTL Consumer Health II
(Switzerland) GmbH | D / LS | FB | | G | |
| L | | IPro | IPat | | Microlax | 12 x 5 ml | 12.45 | 23.00 | 10% | | Lavement: 3 Principes actifs | JNTL Consumer Health II
(Switzerland) GmbH | D / LS / LPPA | FB | | G | |
| L | | IPro | IPat | | Microlax | 50 x 5 ml | 51.88 | 95.80 | 10% | | Lavement: 3 Principes actifs | JNTL Consumer Health II
(Switzerland) GmbH | D / LS / LPPA | FB | | G | |
| L | | IPro | | | Vegzelma 100 mg/4 ml | | 257.57 | 296.55 | 10% | | Concentré pour perfusion: Bevacizumabum 100mg / 4ml | iQone Healthcare
Switzerland SA | A / LS | FB | | G | |
| L | | IPro | | | Vegzelma 400 mg/16 ml | | 962.84 | 1063.55 | 10% | | Concentré pour perfusion: Bevacizumabum 400mg / 16ml | iQone Healthcare
Switzerland SA | A / LS | FB | | G | |
| L | | IPro | IPat | | D3 VitaCaps 24,000 IU
(600 μg) | 6 | 7.65 | 17.55 | 10% | | Capsules molles: Cholecalciferolum 600 µg | Pierre Fabre Pharma SA | B / LS | FB | | G | |
| L | | IPro | | PP | Herceptin subkutan
600mg/5ml | | 1484.04 | 1630.40 | 10% | | Lösung zur subkutanen Injektion: Trastuzumabum 600mg / 5ml | Roche Pharma
(Schweiz) AG | A / LS | FB | | G | |
| L | | IPro | | | Ogivri 150 mg | | 456.84 | 513.25 | 10% | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trastuzumabum 150 mg | Medius AG | A / LS | FB | | G | |
| | | IPro | IPat | | Imodium lingual akut | 10 | DDP | DDP | N.O. | | Comprimés orodispersibles: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II
(Switzerland) GmbH | D | FB | | G | |
| | | IPro | IPat | | Imodium lingual akut | 12 | DDP | DDP | N.O. | | Comprimés orodispersibles: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II
(Switzerland) GmbH | D | FB | | G | |
| | | IPro | IPat | | Nicorette Microtab
Original-Aroma | 100 Comprimé(s) | DDP | DDP | N.O. | | Comprimés sublinguaux: Nicotinum 2 mg | JNTL Consumer Health II
(Switzerland) GmbH | D / LPPA | FB | | G | |
| | | IPro | IPat | | D3 VitaCaps 24,000 IU
(600 μg) | 4 | DDP | DDP | N.O. | | Capsules molles: Cholecalciferolum 600 µg | Pierre Fabre Pharma SA | B | FB | | G | |
| | | IPro | IPat | | D3 VitaCaps 24,000 IU
(600 μg) | 8 | DDP | DDP | N.O. | | Capsules molles: Cholecalciferolum 600 µg | Pierre Fabre Pharma SA | B | FB | | G | |
| | | IPro | IPat | | D3 VitaCaps 24,000 IU
(600 μg) | 12 | DDP | DDP | N.O. | | Capsules molles: Cholecalciferolum 600 µg | Pierre Fabre Pharma SA | B | FB | | G | |
| | | IPro | IPat | | Regaine 5 % | 60 ml | DDP | DDP | N.O. | | Solution: Minoxidilum 50 mg/ml | JNTL Consumer Health II
(Switzerland) GmbH | D / LPPA | FB | | G | |
| | | IPro | IPat | | Regaine 5 % | 3 x 60 ml | DDP | DDP | N.O. | | Solution: Minoxidilum 50 mg/ml | JNTL Consumer Health II
(Switzerland) GmbH | D / LPPA | FB | | G | |
| | | IPro | | | Mylotarg 5 mg | | DDP | DDP | N.O. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Gemtuzumabum Ozogamicinum 5 mg | Pfizer AG | A | FB | | G | |
